Icon plc Stock
€154.50
Your prediction
Icon plc Stock
Pros and Cons of Icon plc in the next few years
Pros
Cons
Performance of Icon plc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Icon plc | -0.480% | 0.673% | 11.190% | -19.156% | -23.601% | -11.299% | - |
| Alkermes plc | 0.000% | -2.459% | -10.526% | -17.361% | -15.000% | 1.623% | 35.227% |
| Ironwood Pharmaceuticals | -0.670% | -1.974% | 9.559% | -7.453% | -29.048% | -73.772% | -69.436% |
| Novocure Ltd | -3.720% | 0.732% | 13.114% | -63.539% | -62.174% | -84.302% | -91.458% |
Comments
News
3 Healthcare Pathbreakers With Long-Term Tailwinds
In the world of healthcare stocks, a major innovation, new medical device, or successful drug treatment can cement a firm's position as a leader. Unfortunately, many firms chase after these goals
LVM Capital Management Dumps 16,000 ICON Public Shares Worth $2.6 million
According to an SEC filing dated July 2, 2025, LVM Capital Management reduced its position in ICON Public Limited (NASDAQ:ICLR) by selling 16,096 shares. The transaction was valued at $2.58 million
ICON and Its Employees Recognised as Clinical Research Industry Leaders, and for Innovation and Progress in Sustainability
ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, has been honoured in the first half of 2025 with a number of business awards, recognising the



